

In the Claims:

In accordance with 37 CFR § 1.121, please substitute for original claims 40 and 48 the following rewritten versions of the same claims, as amended. The changes are shown explicitly in the attached “Marked Up Version Showing Changes Made.” Please also add new claims 58 and 59.

Please amend the following claims.

40. (Amended) A method for making a reshaped human antibody comprising:

(a) providing complementary determining regions derived from a mouse antibody and framework regions derived from a human antibody,

(b) substituting an amino acid residue of position 46 of an L chain numbered according to Kabat with a mouse antigen binding site and

(c) substituting 0-5 amino acid residue(s) on an H chain numbered according to Kabat with a mouse antigen binding site.

48. (Amended) A method for making a single-chain Fv region comprising:

(a) producing a reshaped antibody by substituting an amino acid residue on position 46 of an L chain V region numbered according to Kabat, with a mouse antigen binding site and by substitution 0-5 amino acids of an H chain V region numbered according to Kabat, with a mouse antigen binding site,

(b) linking the L chain V region and the H chain V region with a linker peptide, and

(c) combining identified complementary determining regions from a mouse antibody and framework regions derived from a human antibody, wherein an amino acid residue 46 of L chain V region numbered according to Kabat is a mouse residue and the single chain Fv region creates a functional antigen binding site.

58. (New) A method for making a reshaped human antibody comprising:

(a) providing complementary determining regions identified from a mouse antibody and framework regions identified from a human antibody, and

(b) substituting an amino acid residue of position 46 of an L chain numbered according to Kabat with a mouse antigen binding site and

(c) substituting 0-5 amino acid residue(s) on an H chain numbered according to Kabat with a mouse antigen binding site.

59. (New) A method for making a single-chain Fv region comprising:

(a) producing a reshaped antibody by substituting an amino acid residue on position 46 of an L chain V region numbered according to Kabat, with a mouse antigen binding site and by substitution 0-5 amino acids of an H chain V region numbered according to Kabat, with a mouse antigen binding site,

(b) linking the L chain V region and the H chain V region with a linker peptide, and

(c) combining identified complementary determining regions from a mouse antibody and framework regions identified from a human antibody, wherein an amino acid residue 46 of L chain V region numbered according to Kabat is a mouse residue and the single chain Fv region creates a functional antigen binding site.